报价延迟最少15分钟:2026/06/07 13:25 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.58 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.21/0.34
|
|
企业价值
1.47B
|
| 资产负债 |
|
每股账面净值
0.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.68M
|
|
每股收益
0.06
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
